The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation in the European Union (EU) ...

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of ...

Patients who underwent stem cell transplants (SCTs) involving mismatched unrelated donors (MMUDs) had a 1-year overall ...

During a live event, Nelson J. Chao, MD, discussed key outcomes from the trials supporting the use of ruxolitinib and ...

Mesoblast's RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Graft versus host disease, or GVHD, is a complication of a stem cell transplant, a treatment for blood cancers and certain blood or immune system disorders. With GVHD, white blood cells called T ...

These are the top foods to avoid or limit if you have chronic graft-versus-host disease (GVHD), according to dietitians. These foods may be unsafe or cause gut discomfort.

NeuroScientific Biopharmaceuticals has acquired unlisted Perth-based Isopogen for $5.1 million, gaining control of the ...

Two biomarker tests -- one for blood and the other for stool -- are mainstays in the treatment of inflammatory bowel disease ...

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...